FMP
Canaccord Genuity Slashes Price Target on Rocket Pharmaceuticals to $40
Jul 3, 2024 10:29 PM - Davit Kirakosyan(Last modified: Jul 4, 2024 4:25 AM)
Image credit: FMP
Canaccord Genuity analysts revised their price target for Rocket Pharmaceuticals (NASDAQ:RCKT) down to $40 from $49, while maintaining a Buy rating on the stock. The analysts expressed increased confidence in the success of the Phase 3 trial for DESCARTES-08, leading to a 50% assumed success rate. The price target adjustment also accounts for the additional shares from the $130 million PIPE financing.
The analysts anticipate further trial design refinements in Phase 3, such as excluding seronegative and LRP4+ patients from the primary efficacy analysis, which is expected to enhance the trial's likelihood of success.
Other Blogs
Sep 10, 2024 7:33 AM - Parth Sanghvi
Best Alternatives to Yahoo Finance for Downloading Historical Stock Data
When it comes to downloading historical stock data, Yahoo Finance has been a popular choice for many. However, for those looking for more comprehensive, accurate, and flexible options, Financial Modeling Prep (FMP) offers a suite of powerful tools and services that stand out as superior alternatives...
Nov 8, 2024 5:30 AM - Sanzhi Kobzhan
Understanding Equity Valuation: When to Use DCF, DDM, and Price-Income (Multiplicators) Models
When it comes to investing in stocks, one of the key decisions an investor must make involves determining the intrinsic value of a company's shares. Equity valuation isn't just about numbers, it's an art mixed with science, aiming to predict future performance based on current and historical data. H...
Nov 22, 2024 5:08 AM - Parth Sanghvi
Fundamental Analysis: Principles, Types, and How to Use It
Fundamental analysis is one of the most essential tools for investors and analysts alike, helping them assess the intrinsic value of a stock, company, or even an entire market. It focuses on the financial health and economic position of a company, often using key data such as earnings, expenses, ass...
